Last reviewed · How we verify
NCT05008874: CYGNET
Study of Disease Progression in Adults With Inherited Forms of Spastic Paraplegia
trial testing Natural History Observation in AMN in 65 participants. Terminated before completion.
16 May 2025
Quick facts
| Lead sponsor | SwanBio Therapeutics, Inc. |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 65 |
| Start date | 21 June 2021 |
| Primary completion | 16 May 2025 |
| Estimated completion | 16 May 2025 |
| Sites | 6 locations across Netherlands, United States, Germany |
Drugs / interventions tested
- Natural History Observation
Conditions studied
- AMN — all drugs for AMN →
- AMN Gene Mutation — all drugs for AMN Gene Mutation →
- X-ALD — all drugs for X-ALD →
Sponsor
SwanBio Therapeutics, Inc.
Who can join
18 and older, male only, with AMN or AMN Gene Mutation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The course of AMN-related disabilities over time is poorly or incompletely understood due to a limited number of patients and lack of treatments. This study will help obtain a better understanding of the progression of disease with AMN and facilitate efficient clinical development of future interventional medications.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Elivaldogene autotemcel approved for treatment of cerebral adrenoleukodystrophy (CALD) in males: A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG).
Scott AI, Mallhi KK, Ganesh J, Chen WL, et al · · 2023 · cited 4× · PMID 39669257 · DOI 10.1016/j.gimo.2023.100835
Verify or expand the search:
- PubMed search for NCT05008874
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Natural History Observation
Trials testing the same drug.
- NCT05095623 — A Natural History Study to Assess the Clinical Outcomes of Patients With Complement Factor I Deficiency-Mediated Disease · terminated
Other recruiting trials for AMN
Currently open trials in the same condition.
- NCT03047369 — The Myelin Disorders Biorepository Project · recruiting
Other SwanBio Therapeutics, Inc. trials
Trials by the same sponsor.
- NCT05394064 — A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN) · Phase 1, PHASE2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05008874 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by SwanBio Therapeutics, Inc.
- Last refreshed: 30 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05008874.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing